.svg)
___________
Introduction
Endpoint Clinical has been named a Leader in Everest Group’s Life Sciences Randomization and Trial Supply Management (RTSM) Products PEAK Matrix® Assessment 2025. This recognition is more than a ranking. It reflects the critical role RTSM providers play in shaping the future of clinical trials.
The PEAK Matrix® Assessment is widely regarded as a benchmark for excellence. It evaluates providers across two dimensions:
For life sciences organizations, this acknowledgment signals confidence in Endpoint’s ability to combine advanced technology with operational agility to help sponsors and CROs manage complexity while safeguarding patient integrity and accelerating timelines.
Clinical trials are evolving rapidly. Global and adaptive designs introduce new layers of complexity, requiring platforms that do far more than randomize patients. Today’s RTSM systems must manage supply chains, integrate seamlessly with eClinical ecosystems, and adapt quickly to protocol changes. What began as basic IVR/IWRS tools has matured into intelligent, cloud-based solutions that serve as the operational backbone for modern trials.
Everest Group’s assessment highlights providers that deliver both market impact and technology maturity. Endpoint’s leadership position reflects its ability to enable speed, accuracy, and resilience in an environment where delays and inefficiencies can directly affect patient outcomes.
Endpoint’s RTSM platform is designed to address the most pressing challenges in clinical research. Its low-code configuration and flexible architecture allow rapid mid-study amendments without disrupting timelines. Real-time inventory visibility, automated shipment triggers, and dynamic forecasting reduce risk and ensure uninterrupted patient access. AI-driven features such as automated UAT, protocol parsing, and virtual support assistants streamline processes and minimize manual intervention. Acting as a single source of truth, Endpoint’s RTSM connects eClinical and logistics systems for unified data integrity and compliance.
These capabilities do more than improve operational efficiency. They protect patient safety and enhance the overall patient experience by ensuring timely drug availability and reducing operational errors. Every advancement is aimed at maintaining trust and continuity for patients who depend on these therapies.
Recognition as a Leader underscores a broader shift: RTSM is no longer a back-office function; it is the air traffic controller for clinical data. It has become a strategic enabler for accelerating drug development and maintaining quality in increasingly complex trials. Providers that invest in automation, predictive analytics, and integration will set the pace for the next generation of clinical research. Most importantly, these innovations ultimately serve patients by reducing delays, improving access, and supporting better health outcomes.
Endpoint’s long-term vision is clear: to lead the transformation of clinical trial operations in a way that prioritizes patients above all else. Technology and innovation are essential, but they only matter when they translate into better experiences and outcomes for the individuals at the center of every study. This recognition from Everest Group reinforces that mission and strengthens our commitment to bringing lifesaving drugs to patients as the ultimate measure of success.
Endpoint’s RTSM leadership highlights innovation shaping the future of clinical trials
A Collaborative Vision from Moderna and Endpoint Clinical
Endpoint’s Support Squad: Your 24/7 Clinical Trial Lifeline
